Allicin as a Volatile or Nebulisable Antimycotic for the Treatment of Pulmonary Mycoses: In Vitro Studies Using a Lung Flow Test Rig

Int J Mol Sci. 2022 Jun 14;23(12):6607. doi: 10.3390/ijms23126607.

Abstract

Fungal infections of the lung are an increasing problem worldwide and the search for novel therapeutic agents is a current challenge due to emerging resistance to current antimycotics. The volatile defence substance allicin is formed naturally by freshly injured garlic plants and exhibits broad antimicrobial potency. Chemically synthesised allicin was active against selected fungi upon direct contact and via the gas phase at comparable concentrations to the pharmaceutically used antimycotic amphotericin B. We investigated the suppression of fungal growth by allicin vapour and aerosols in vitro in a test rig at air flow conditions mimicking the human lung. The effect of allicin via the gas phase was enhanced by ethanol. Our results suggest that allicin is a potential candidate for development for use in antifungal therapy for lung and upper respiratory tract infections.

Keywords: Paecilomyces; allicin; antimycotic; lung infection; mycosis.

MeSH terms

  • Disulfides
  • Humans
  • Lung
  • Mycoses* / drug therapy
  • Sulfinic Acids* / chemistry
  • Sulfinic Acids* / pharmacology
  • Sulfinic Acids* / therapeutic use

Substances

  • Disulfides
  • Sulfinic Acids
  • allicin